Basic Information
| LncRNA/CircRNA Name | XIST |
| Synonyms | XIST, DXS1089, DXS399E, LINC00001, NCRNA00001, SXI1, swd66 |
| Region | GRCh38_X:73820651-73852753 |
| Ensemble | ENSG00000229807 |
| Refseq | NR_001564 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | colorectal cancer |
| ICD-0-3 | C19.9 |
| Methods | qPCR, Western blot |
| Sample | The human colorectal cancer cell lines (HT29, HCT116, FHC) |
| Expression Pattern | up-regulated |
| Function Description | In conclusion, our integrated approach demonstrates that increased expression of lncRNA XIST3 in CRC confers a potent poor therapeutic efficacy, and that lncRNA XIST participated in 5FU resistance through promoting the expression of thymidylate synthase. Thus, specific silence oflncRNA XIST could be a future direction to develop a novel therapeutic strategy to overcome 5FU resistance of CRC patients.In addition, increased serum XIST level was associated with poor response and lower survival rate in CRC patients receiving 5FU-based treatment. However, nearly all patients receiving chemotherapy finally develop drug resistance, and this has been a major obstacle to improving the efficiency of colorectal cancer treatment. TS functions during the reductive methylation of deoxyuridine monophosphate to deoxythymidine monophosphate, with low level of folate 5,10-methylenetetrahydrofolate as the methyl donor. |
| Pubmed ID | 29137332 |
| Year | 2017 |
| Title | Long noncoding RNA XIST is a prognostic factor in colorectal cancer and inhibits 5-fluorouracil-induced cell cytotoxicity through promoting thymidylate synthase expression. |
External Links
| Links for XIST | GenBank HGNC NONCODE |
| Links for colorectal cancer | OMIM COSMIC |